TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET 26
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 TEST TYPE SEGMENT LIFELINE CURVE 37
2.8 MARKET END USER COVERAGE GRID 38
2.9 DBMR MARKET POSITION GRID 39
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47
6 REGULATORY FRAMEWORK 49
6.1 REGULATORY SCENARIO IN THE U.S 49
7 MARKET OVERVIEW 50
7.1 DRIVERS 52
7.1.1 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY 52
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 52
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 53
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 54
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 54
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 54
7.3 OPPORTUNITIES 55
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 55
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 55
7.3.3 INCREASE IN THE GERIATRIC POPULATION 56
7.4 CHALLENGES 56
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 56
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 57
8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 58
8.1 OVERVIEW 59
8.2 CYSTOSCOPY 62
8.3 URINE LAB TEST 62
8.3.1 URINE CYTOLOGY 64
8.3.2 URINALYSIS 64
8.3.3 URINE TUMOR MARKER TEST 64
8.3.4 URINE CULTURE 64
8.3.5 OTHERS 64
8.4 BIOPSY 64
8.5 IMAGING TEST 65
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 66
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 66
8.5.3 ULTRASOUND 66
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 67
8.6 OTHERS 67
9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 68
9.1 OVERVIEW 69
9.2 STAGE IV 72
9.3 STAGE III 72
9.4 STAGE II 73
9.5 STAGE I 74
10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 76
10.1 OVERVIEW 77
10.2 TRANSITIONAL CELL BLADDER CANCER 80
10.3 SQUAMOUS CELL BLADDER CANCER 81
10.4 OTHER CANCER TYPES 82
11 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 83
11.1 OVERVIEW 84
11.2 HOSPITAL 87
11.3 DIAGNOSTIC IMAGING CENTERS 87
11.4 CANCER RESEARCH INSTITUTES 88
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 89
11.6 ASSOCIATED LABS 90
12 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 91
12.1 OVERVIEW 92
12.2 DIRECT TENDER 95
12.3 RETAIL SALES 95
13 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 97
13.1 NORTH AMERICA 98
13.1.1 U.S. 105
13.1.2 CANADA 107
13.1.3 MEXICO 109
14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 111
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111
15 SWOT ANALYSIS 112
16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET 113
16.1 F. HOFFMANN- LA ROCHE LTD 113
16.1.1 COMPANY SNAPSHOT 113
16.1.2 REVENUE ANALYSIS 113
16.1.3 COMPANY SHARE ANALYSIS 114
16.1.4 PRODUCT PORTFOLIO 114
16.1.5 RECENT DEVELOPMENTS 114
16.2 MERCK KGAA 115
16.2.1 COMPANY SNAPSHOT 115
16.2.2 REVENUE ANALYSIS 115
16.2.3 COMPANY SHARE ANALYSIS 116
16.2.4 PRODUCT PORTFOLIO 116
16.2.5 RECENT DEVELOPMENT 116
16.3 THERMO FISHER SCIENTIFIC INC. 117
16.3.1 COMPANY SNAPSHOT 117
16.3.2 REVENUE ANALYSIS 117
16.3.3 COMPANY SHARE ANALYSIS 118
16.3.4 PRODUCT PORTFOLIO 118
16.3.5 RECENT DEVELOPMENT 118
16.4 KONINLIJKE PHILIPS N.V. 119
16.4.1 COMPANY SNAPSHOT 119
16.4.2 REVENUE ANALYSIS 119
16.4.3 COMPANY SHARE ANALYSIS 120
16.4.4 PRODUCT PORTFOLIO 120
16.4.5 RECENT DEVELOPMENT 120
16.5 BIO-RAD LABORATORIES, INC. 121
16.5.1 COMPANY SNAPSHOT 121
16.5.2 COMPANY SNAPSHOT 121
16.5.3 COMPANY SHARE ANALYSIS 122
16.5.4 PRODUCT PORTFOLIO 122
16.5.5 RECENT DEVELOPMENT 122
16.6 ABBOTT 123
16.6.1 COMPANY SNAPSHOT 123
16.6.2 REVENUE ANALYSIS 123
16.6.3 PRODUCT PORTFOLIO 124
16.6.4 RECENT DEVELOPMENT 124
16.7 AGILENT TECHNOLOGIES, INC. 125
16.7.1 COMPANY SNAPSHOT 125
16.7.2 REVENUE ANALYSIS 125
16.7.3 PRODUCT PORTFOLIO 126
16.7.4 RECENT DEVELOPMENT 126
16.8 AMBU A/S 127
16.8.1 COMPANY SNAPSHOT 127
16.8.2 REVENUE ANALYSIS 127
16.8.3 PRODUCT PORTFOLIO 128
16.8.4 RECENT DEVELOPMENT 128
16.9 BD 129
16.9.1 COMPANY SNAPSHOT 129
16.9.2 REVENUE ANALYSIS 129
16.9.3 PRODUCT PORTFOLIO 130
16.9.4 RECENT DEVELOPMENT 130
16.10 CANON MEDICAL SYSTEMS CORPORATION 131
16.10.1 COMPANY SNAPSHOT 131
16.10.2 REVENUE ANALYSIS 131
16.10.3 PRODUCT PORTFOLIO 132
16.10.4 RECENT DEVELOPMENT 132
16.11 CEPHEID 133
16.11.1 COMPANY SNAPSHOT 133
16.11.2 REVENUE ANALYSIS 133
16.11.3 PRODUCT PORTFOLIO 134
16.11.4 RECENT DEVELOPMENTS 134
16.12 FUJIFILM CORPORATION 135
16.12.1 COMPANY SNAPSHOT 135
16.12.2 REVENUE ANALYSIS 135
16.12.3 PRODUCT PORTFOLIO 136
16.12.4 RECENT DEVELOPMENTS 136
16.13 GENERAL ELECTRIC COMPANY 137
16.13.1 COMPANY SNAPSHOT 137
16.13.2 REVENUE ANALYSIS 137
16.13.3 PRODUCT PORTFOLIO 138
16.13.4 RECENT DEVELOPMENTS 138
16.14 HOLOGIC INC. 139
16.14.1 COMPANY SNAPSHOT 139
16.14.2 REVENUE ANALYSIS 139
16.14.3 PRODUCT PORTFOLIO 140
16.14.4 RECENT DEVELOPMENT 140
16.15 ILLUMINA INC 141
16.15.1 COMPANY SNAPSHOT 141
16.15.2 REVENUE ANALYSIS 141
16.15.3 PRODUCT PORTFOLIO 142
16.15.4 RECENT DEVELOPMENTS 142
16.16 MINFOUND MEDICAL SYSTEMS CO., 143
16.16.1 COMPANY SNAPSHOT 143
16.16.2 PRODUCT PORTFOLIO 143
16.16.3 RECENT DEVELOPMENTS 143
16.17 NEUSOFT CORPORATION 144
16.17.1 COMPANY SNAPSHOT 144
16.17.2 COMPANY SNAPSHOT 144
16.17.3 PRODUCT PORTFOLIO 145
16.17.4 RECENT DEVELOPMENT 145
16.18 QIAGEN 146
16.18.1 COMPANY SNAPSHOT 146
16.18.2 REVENUE ANALYSIS 146
16.18.3 PRODUCT PORTFOLIO 147
16.18.4 RECENT DEVELOPMENT 147
16.19 SIEMENS HEALTHCARE GMBH 148
16.19.1 COMPANY SNAPSHOT 148
16.19.2 REVENUE ANALYSIS 148
16.19.3 PRODUCT PORTFOLIO 149
16.19.4 RECENT DEVELOPMENT 150
16.20 TIME MEDICAL HOLDING. 151
16.20.1 COMPANY SNAPSHOT 151
16.20.2 PRODUCT PORTFOLIO 151
16.20.3 RECENT DEVELOPMENTS 151
17 QUESTIONNAIRE 152
18 RELATED REPORTS 155

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.